{"id":14841,"date":"2021-12-14T18:32:10","date_gmt":"2021-12-14T13:02:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=14841"},"modified":"2021-12-14T18:33:18","modified_gmt":"2021-12-14T13:03:18","slug":"pharma-news-for-pfizer-takeda-novartis-roche","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche","title":{"rendered":"Pfizer to acquire Arena Pharma; Takeda&#8217;s &#8216;Wave 2&#8217; multiple myeloma med data; Novartis&#8217;s next-gen CAR-Ts clinical data; Roche unveils Avenio system"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f332f7e127d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f332f7e127d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche\/#Pfizer_acquires_drugmaker_Arena_for_USD_67_billion_to_address_unmet_needs\" >Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche\/#Takeda_previews_early_response_data_for_%E2%80%98Wave_2_multiple_myeloma_med_in_follow-up_to_Velcade\" >Takeda previews early response data for &#8216;Wave 2&#8217; multiple myeloma med in follow-up to Velcade<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche\/#Roche_unveils_Avenio_system_to_automate_DNA_sequencing_sample_preparation\" >Roche unveils Avenio system to automate DNA sequencing sample preparation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche\/#Novartis_rolls_out_early_data_for_a_pair_of_%E2%80%98second-gen_CAR-Ts_with_more_productive_cells\" >Novartis rolls out early data for a pair of &#8216;second-gen&#8217; CAR-Ts with more productive cells&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-acquires-drugmaker-arena-for-usd-6-7-billion-to-address-unmet-needs\"><span class=\"ez-toc-section\" id=\"Pfizer_acquires_drugmaker_Arena_for_USD_67_billion_to_address_unmet_needs\"><\/span><strong>Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on hand. It will reimburse USD 100 per share of Arena stock and anticipates the contract to close early next year. Officials said the boards of both companies have already approved the acquisition.<\/p>\n\n\n\n<p>Arena is a clinical-stage company that develops therapies for immuno-inflammatory diseases and gastroenterology, <a href=\"https:\/\/www.delveinsight.com\/blog\/companies-investigating-gene-therapy-in-dermatology\">dermatology<\/a>, and cardiology conditions. Pfizer CEO Albert Bourla said that the Arena acquisition lets the company address unmet needs for varying diseases. <\/p>\n\n\n\n<p>One of Arena&#8217;s newest treatments, <a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\">Etrasimod<\/a>, is utilized to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-market\">ulcerative colitis<\/a> and <a href=\"https:\/\/www.delveinsight.com\/blog\/crohns-disease-market\">Crohn&#8217;s disease<\/a>. Pfizer has also been developing ulcerative colitis treatment that affects nearly 3 million people in the United States.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Takeda_previews_early_response_data_for_%E2%80%98Wave_2_multiple_myeloma_med_in_follow-up_to_Velcade\"><\/span><strong>Takeda previews early response data for &#8216;Wave 2&#8217; multiple myeloma med in follow-up to Velcade<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Takeda is seeking its next shot at <a href=\"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-market\">multiple myeloma<\/a> beyond Velcade and is now previewing some early data highlighting partial responses in 38% of patients in one dose group for the next-in-line candidate modakafusp alfa.&nbsp;<\/p>\n\n\n\n<p>According to Takeda, the outcomes are from 29 patients who were part of the 1.5mg\/kg cohort of the phase 1 study. Modakafusp alfa induced complete response in two of 29 patients and excellent partial response in six patients. Three patients in the early-stage research experienced a partial response. The drug is being tested in <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-multiple-myeloma-market\">relapsed\/refractory multiple myeloma<\/a> people who have undergone at least three previous lines of treatment.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-ajinomot-pfizer-ikena-lilly-bright-peak\">immunocytokine therapy<\/a>, a type of treatment fusing cytokines to a monoclonal antibody, is Takeda&#8217;s attempt to establish a unique role in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma market<\/a>. The Japanese Big Pharma is going after a different portion of the cancer-progressing protein CD38 than approved treatments like Johnson &amp; Johnson&#8217;s Darzalex and Sanofi&#8217;s Sarclisa.&nbsp;<\/p>\n\n\n\n<p>For the 11 patients, or 38%, who had a partial response or more significant, it took the drug a median of one month to take effect, and the best response took a median of two months. The 29 patients went a median of 5.7 months without experiencing an exacerbation of the disease.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_unveils_Avenio_system_to_automate_DNA_sequencing_sample_preparation\"><\/span><strong>Roche unveils Avenio system to automate DNA sequencing sample preparation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Next-generation sequencing has revolutionized the field of medicine, with labs now able to look through a patient\u2019s entire genome to identify even the tiniest indicators of disease. And while this technology works remarkably quickly compared to traditional diagnostic methods, it still needs much dedicated time and effort to prepare DNA samples for processing.<\/p>\n\n\n\n<p>However, Roche\u2019s newest offering zeroes in on cutting down on that preparation time. The Avenio Edge system launched this week automates the entire process of readying DNA samples and sequencing libraries for analysis but halts short of performing the actual research.<\/p>\n\n\n\n<p>The all-in-one system enables constant tracking of each sample and integrates directly into laboratory information systems for real-time delivery of the preparation workflow\u2019s results.<\/p>\n\n\n\n<p>According to Roche, the system decreases the hands-on time needed to prepare samples for sequencing by about 84%. A study to assess the system found that the automated workflow can replace a total of 384 manual steps needed to prep 24 DNA libraries for analysis in just one run.<\/p>\n\n\n\n<p>Additionally, Avenio Edge arrives at sequencing labs equipped with ready-to-use components, requiring only about 20 minutes from setup first to use.<\/p>\n\n\n\n<p>Because the system is entirely automated, it also helps eliminate human error in DNA sequencing. Roche said Avenio Edge could decrease error opportunity by more than 96%, preventing labs from recollecting samples, which may be rejected due to mistakes made during manual preparations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_rolls_out_early_data_for_a_pair_of_%E2%80%98second-gen_CAR-Ts_with_more_productive_cells\"><\/span><strong>Novartis rolls out early data for a pair of &#8216;second-gen&#8217; CAR-Ts with more productive cells&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current generation of cell therapies has been a game-changer in treating aggressive blood cancers. However, the tech has its restrictions. Novartis is one of the biggies in the current generation of these drugs and is now taking lessons learned from <a href=\"https:\/\/www.delveinsight.com\/report-store\/kymriah-drug-insight-and-market-forecast\">CAR-T Kymriah<\/a> to supercharge a <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-pipeline-insight\">second-generation of CAR-Ts<\/a> putting superior cells into patients faster.&nbsp;<\/p>\n\n\n\n<p>Novartis rolled out early Phase I data for a pair of <a href=\"https:\/\/www.delveinsight.com\/blog\/car-t-cell-therapy-market-and-competitive-landscape\">autologous CAR-T cell therapies<\/a> created via the drugmaker\u2019s T-Charge platform, a process designed to promote T cell stemness, which is a measure of a cell\u2019s ability to self-renew by cutting manufacturing times and spurring cell proliferation primarily in patients\u2019 lymph nodes.<\/p>\n\n\n\n<p>These second-generation CAR-Ts, a CD19-targeted drug dubbed YTB323 and a BCMA-directed candidate named PHE885, represent Novartis\u2019 lessons learned from first-gen CAR Kymriah as well as an answer to the difficult manufacturing and supply chain concerns endemic to present drugs in this class on the market. With this platform, Novartis contemplates it can halve its existing manufacturing timeline, what is called vein-to-door, over existing CAR-Ts while removing the requirement for bridging chemo, said Jeff Legos, Novartis\u2019 global head of oncology and hematology development.<\/p>\n\n\n\n<p>For YTB323, Novartis displayed data from 15 patients with third-line-or-later <a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\">diffuse large B cell lymphoma<\/a> monitored for at least three months, with the drug posting a 73% complete response rate at the higher of two dose levels in that early cut. This Phase I dose-escalation study will eventually enroll 110 patients across third-line DLBCL as well as second-line-or-later <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-lymphocytic-leukemia-all-market\">acute lymphocytic leukemia<\/a> or chronic lymphocytic lymphoma\/small lymphocytic lymphoma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on hand. It will reimburse USD 100 [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":14844,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[810,1257,667,410,420,639,16410],"industry":[17225],"therapeutic_areas":[17235,17239,17233,17228],"class_list":["post-14841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-car-t","tag-car-t-therapy","tag-lymphoma","tag-multiple-myeloma","tag-news","tag-pharma-news","tag-ulcerative-colitis","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-gastroenterology","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pfizer to buy Arena; Roche&#039;s Avenio system; Novartis&#039;s next-gen CAR-T<\/title>\n<meta name=\"description\" content=\"Pfizer to acquire Arena Pharma; Roche unveils Avenio system; Takeda&#039;s &#039;Wave 2&#039; multiple myeloma med data; Novartis&#039;s next-gen CAR-Ts\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer to buy Arena; Roche&#039;s Avenio system; Novartis&#039;s next-gen CAR-T\" \/>\n<meta property=\"og:description\" content=\"Pfizer to acquire Arena Pharma; Roche unveils Avenio system; Takeda&#039;s &#039;Wave 2&#039; multiple myeloma med data; Novartis&#039;s next-gen CAR-Ts\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-14T13:02:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-14T13:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/14181003\/Pharma-news-30.11.2021-772-x-482-px.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer to buy Arena; Roche's Avenio system; Novartis's next-gen CAR-T","description":"Pfizer to acquire Arena Pharma; Roche unveils Avenio system; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche","og_locale":"en_US","og_type":"article","og_title":"Pfizer to buy Arena; Roche's Avenio system; Novartis's next-gen CAR-T","og_description":"Pfizer to acquire Arena Pharma; Roche unveils Avenio system; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-12-14T13:02:10+00:00","article_modified_time":"2021-12-14T13:03:18+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/14181003\/Pharma-news-30.11.2021-772-x-482-px.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche","name":"Pfizer to buy Arena; Roche's Avenio system; Novartis's next-gen CAR-T","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/14181003\/Pharma-news-30.11.2021-772-x-482-px.png","datePublished":"2021-12-14T13:02:10+00:00","dateModified":"2021-12-14T13:03:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Pfizer to acquire Arena Pharma; Roche unveils Avenio system; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-pfizer-takeda-novartis-roche#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/14181003\/Pharma-news-30.11.2021-772-x-482-px.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/14181003\/Pharma-news-30.11.2021-772-x-482-px.png","width":772,"height":482,"caption":"pharma-news-for-pfizer-takeda-novartis-roche"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/12\/14181003\/Pharma-news-30.11.2021-772-x-482-px-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">CAR-T therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Ulcerative colitis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">CAR-T therapy<\/span>","<span class=\"advgb-post-tax-term\">lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative colitis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Dec 14, 2021","modified":"Updated on Dec 14, 2021"},"absolute_dates_time":{"created":"Posted on Dec 14, 2021 6:32 pm","modified":"Updated on Dec 14, 2021 6:33 pm"},"featured_img_caption":"pharma-news-for-pfizer-takeda-novartis-roche","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/14841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=14841"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/14841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/14844"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=14841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=14841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=14841"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=14841"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=14841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}